The Wegovy Pill and Its Price Tag

Novo Nordisk sells the pill version of Wegovy, to people paying out of pocket, for less than it sells the shot. According to Disclosed Labs, “As of October 21, 2026, the self-pay price for Wegovy via NovoCare Pharmacy starts at $149/month for the pill formulation and $199/month for the pen formulation.” The pill is oral semaglutide. The FDA approved it in December 2025 for chronic weight management, and in its 64-week trial it produced about 14% average weight loss. Same molecule as the pen. Different box.

If you came here looking for a wegovy pill coupon, the available sources describe something else. They describe a self-pay price through Novo’s own pharmacy channel, not a coupon in the cut-it-out-and-hand-it-over sense. Whether a separate savings card stacks on top of the $149 is not something these sources settle. What they do settle is that $149 is a brand price, set by the company that holds the patents. There is no generic Wegovy pill in the US, and the patent dates say there will not be one soon.

The Wegovy pill coupon question, read like a contract

The whole subject fits inside that one sentence from Disclosed Labs, so I am going to read it the way a lawyer reads an indemnity clause, slowly and with suspicion. (Reading single sentences too closely is most of my job, which is not a great sign.) There are five operative pieces.

“As of October 21, 2026.” The sentence speaks for a single day. It makes no representation regarding October 22, and a careful reader shall not imply one. Prices like this are announced, not promised, and the date is the sentence being honest about that.

“The self-pay price.” This is the price for people outside insurance, outside Medicare, outside any system with a professional negotiator. It is the price you get when the only party across the table from Novo Nordisk is one person with a credit card.

“Via NovoCare Pharmacy.” The seller is the manufacturer’s own pharmacy channel. The line between “drug company” and “pharmacy” is, in this arrangement, a bit blurry, the way the line between a restaurant and the chef’s cousin who runs the wine list is blurry. That’s fine. It just means the price, the pharmacy and any savings offer all come out of the same building.

“Starts at.” This is the phrase on every airline fare and every new-car ad, and it means the same thing here: at least one version of this product exists at this price, and the sentence does not say which one or what the others cost. Here is an invented scenario, clearly made up. A literal-minded patient reads “starts at $149” and asks to buy only the start. A literal-minded pharmacy ships the first pill of the month at the starting price and prices the second at the next tier, and the third at the tier after that, until by pill thirty the patient has climbed a staircase of tiers the sentence never mentioned (and the pharmacy has invented several new ones to keep up). Nobody would do this. The wording just leaves room for it.

“$149/month for the pill formulation and $199/month for the pen formulation.” The pill is $50 cheaper. That’s the weird part.

Why the self-pay price sits below Medicare’s

Ozempic, Rybelsus and Wegovy were included in the second round of Medicare drug price negotiations under the Inflation Reduction Act. The negotiated price for the three is $274 per 30-day supply, effective January 1, 2027, a 71% cut from the 2024 list price of $959.

So in some sense the federal government, with a statute and a whole negotiating process behind it, ended up with a number higher than the one a person with a credit card can see from Novo. (The comparison is rough: the sources do not say whether the Medicare price covers the pill, and “starts at” is not “costs.”) Still. The biggest buyer in American health care bargained hard and landed $125 above the bottom of the self-pay menu.

One reading is that this is a market-building price: get people onto the drug, and onto the pill, before anything cheaper exists, while the list price stays where it is for every insurer that pays it. The other reading is that the price is defensive, set at the point where people who would otherwise go elsewhere stop going elsewhere (compounding pharmacies, for instance, sold injectable semaglutide for an average of $230 a month). You can picture someone in a pricing meeting saying, “Okay, we’re under the compounders and under Medicare, is anyone going to ask why the pill is cheaper than the pen?” I don’t know which reading is right. They are not exclusive.

Why the pill is not cheaper to make, for pricing purposes

The natural guess is that the pill costs less because pills are simple and pens are fiddly little machines. The sources here do not say what either one costs to make, and this site leaves manufacturing to others. But the guess is beside the point anyway, because in the US this price is not set by cost. It is set by exclusivity.

The pill is semaglutide. So is the pen. So is Ozempic. They share the compound patent, US 8,129,343, extended through patent term restoration to December 5, 2031, and Novo said in its 2025 Form 20-F that the US compound expiry for Ozempic, Rybelsus and Wegovy is 2032. The extension rule is strict: DrugPatentWatch notes that “Wegovy and Rybelsus cannot receive a second extension on the same semaglutide compound patent.” One molecule, one extension.

That cuts both ways. The pill does not get its own longer core monopoly, but it does not escape the shared one either. Secondary patents stretch to 2038, and one listed patent, “Semaglutide For Use In Medicine,” runs to May 13, 2040, though that listing names Wegovy and Wegovy Flextouch (the injectable products) and the sources do not say which patents, if any, read on the pill. Presumably someone will litigate that. Not settled.

What generic entry did to Wegovy in India

India is the clearest picture of what happens when the patent actually ends. Over 40 generic semaglutide brands launched there on March 21, 2026, the day after expiry. On April 1, about ten days later, Novo cut the price of the Wegovy starting dose by 48%, and Ozempic by 36%. That followed an earlier cut, in November 2025, of up to 37%, which took the Wegovy starting pack from Rs 16,261 (roughly $190) to Rs 10,850 (roughly $125).

By October 8, 2026, the lowest stated monthly price for generic semaglutide in India was Rs 1,290, roughly $15, for vials from Natco and Eris. Stuff gets cheap fast.

So generic entry did not merely add cheaper options. It moved the brand. A 48% cut in ten days is not a company discovering that its costs fell; it is a company discovering that it has competitors. Canada is heading the same direction (Health Canada authorized Apotex’s Sevmia, a generic of the Wegovy injection, on June 29, 2026), which other pieces on this site cover. None of these generics is a pill, by the way. They are injections and vials.

When a cheaper US pill could arrive

On the dates in these sources, a generic oral semaglutide in the US is a 2032 story at the earliest for the molecule, with the secondary patents an open question after that. Until then, the cheapest pill is the one Novo chooses to sell cheaply, through its own pharmacy, as of a given date, starting at a given price, or whatever the next dated sentence says.

That makes the $149 price less like a coupon and more like a press release with a checkout button. It is real money and a real price, and it sits entirely at the discretion of the patent holder. In India, that discretion ended on March 21.

For now the discount and the monopoly are the same thing.